This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Waris, G.
Right arrow Articles by Siddiqui, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Waris, G.
Right arrow Articles by Siddiqui, A.

 Previous Article  |  Next Article 

Journal of Virology, August 2007, p. 8122-8130, Vol. 81, No. 15
0022-538X/07/$08.00+0     doi:10.1128/JVI.00125-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Hepatitis C Virus Induces Proteolytic Cleavage of Sterol Regulatory Element Binding Proteins and Stimulates Their Phosphorylation via Oxidative Stress{triangledown}

Gulam Waris,1,{dagger} Daniel Jeffery Felmlee,1 Francesco Negro,2 and Aleem Siddiqui1*

Department of Medicine, Division of Infectious Diseases, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093,1 Departments of Internal Medicine and Pathology and Immunology, University of Geneva Medical Center, 1 rue Michel-Servet, Geneva 1205, Switzerland2

Received 18 January 2007/ Accepted 5 May 2007


arrow
ABSTRACT
 
Hepatic steatosis is a common histological feature of chronic hepatitis C. Hepatitis C virus (HCV) gene expression has been shown to alter host cell cholesterol/lipid metabolism and thus induce hepatic steatosis. Since sterol regulatory element binding proteins (SREBPs) are major regulators of lipid metabolism, we sought to determine whether genotype 2a-based HCV infection induces the expression and posttranslational activation of SREBPs. HCV infection stimulates the expression of genes related to lipogenesis. HCV induces the proteolytic cleavage of SREBPs. HCV core and NS4b derived from genotype 3a are also individually capable of inducing the proteolytic processing of SREBPs. Further, we demonstrate that HCV stimulates the phosphorylation of SREBPs. Our studies show that HCV-induced oxidative stress and subsequent activation of the phosphatidylinositol 3-kinase (PI3-K)-Akt pathway and inactivation (phosphorylation) of PTEN (phosphatase and tensin homologue) mediate the transactivation of SREBPs. HCV-induced SREBP-1 and -2 activities were sensitive to antioxidant (pyrrolidine dithiocarbamate), Ca2+ chelator 1,2-bis(aminophenoxy)ethane-N,N,N',N'-tetraacetic acid-tetra(acetoxymethyl) ester (BAPTA-AM), and PI3-K inhibitor (LY294002). Collectively, these studies provide insight into the mechanisms of hepatic steatosis associated with HCV infection.


arrow
INTRODUCTION
 
Chronic liver disease resulting from hepatitis C virus (HCV) infection represents a major global health problem. HCV infection leads to chronic hepatitis in up to 60 to 80% of infected adults and progresses to liver fibrosis, cirrhosis, and eventually hepatocellular carcinoma (9). The HCV genome is a 9.6-kb positive-sense single-stranded RNA molecule containing a 5' untranslated region (UTR), a single open reading frame, and a 3' UTR (4, 32). The 5' UTR contains an internal ribosome entry site, which directs cap-independent translation of a polyprotein precursor of ~3,000 amino acids that is cleaved by viral proteases and host cell signal peptidases into mature structural proteins (core, E1, and E2) and nonstructural proteins (p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B) (4). An additional viral protein found by ribosomal frameshift has been reported elsewhere (43). Study of the molecular mechanisms of HCV replication and pathogenesis has been hampered by the lack of an efficient cell culture system and a small-animal model. A robust and productive HCV (genotype 2a) infection system has been demonstrated which allows the production of virus in tissue culture (27, 39, 46).

Hepatosteatosis is strongly associated with HCV infection, occurring in approximately 50% of HCV-infected patients (34). Previous studies suggest that HCV has a direct role in the development of steatosis and that the presence of steatosis affects the progression of HCV-related liver disease. Steatosis is present in 73% of patients infected with HCV genotype 3 and in 50% of patients infected with genotypes other than 3 (1, 19). The molecular mechanisms underlying HCV-induced steatosis are not well understood. Using the subgenomic replicon derived from genotype 1b, we have previously shown that the HCV translation/replication activities alter lipid homeostasis through inhibition of microsomal triglyceride transfer protein (MTP) activity and very-low-density lipoprotein secretion (10).

Sterol regulatory element binding proteins (SREBPs) are endoplasmic reticulum (ER) membrane-bound transcription factors that activate genes encoding the enzymes that regulate the synthesis of cholesterol and fatty acids and cellular uptake of lipoproteins (7, 18). There are three SREBP isoforms, designated SREBP-1a, SREBP-1c, and SREBP-2 (18). SREBP-1c is regulated by liver X receptors (LXRs), insulin, and glucagons (18, 44). LXR activity is regulated by binding of oxysterol ligands. SREBP-1c and SREBP-2 activate genes involved in fatty acid and cholesterol biosynthesis, respectively, whereas SREBP-1a activates target genes in both pathways (18). SREBPs are synthesized as membrane-bound precursors and exist in complex with SREBP cleavage-activating protein (SCAP) (7, 44). SCAP is both an escort for SREBPs and a sensor of ER membrane sterol concentration. When cholesterol levels decrease, the SREBP-SCAP complex dissociates from the ER retention protein INSIG and transits to the Golgi compartment, where site 1 and site 2 proteases act specifically and sequentially to cleave the SREBPs (25). The amino (N)-terminal cleaved SREBP fragment translocates to the nucleus to activate transcription of genes required for sterol biosynthesis. SREBPs bind to sterol response elements (SREs) located in the promoters of genes involved in lipogenesis (18).

In the present study, we investigate the mechanism(s) of SREBP-1/2 activation in response to Ca2+ signaling and oxidative stress induced by HCV infection. Our results show that activation of phosphatidylinositol 3-kinase (PI3-K)-Akt and LXR are involved in the activation of SREBPs. These data collectively suggest a novel mechanism(s) of SREBP activation associated with HCV-induced steatosis.


arrow
MATERIALS AND METHODS
 
Plasmids, antibodies, and reagents. The pSynSRE-Luc plasmid containing three SREs (–325 to –225 bp of the hamster high-mobility group [HMG] coenzyme A [CoA] synthase promoter fused into the luciferase pGL2), the JS-15 plasmid (identical to pSynSRE, except with a double point mutation in SRE binding sites), the fatty acid synthase (FAS) promoter construct (wild-type, FAS-700-Luc), and FAS-700-SRE mut-Luc with mutated SREBP-1 binding sites were kind gifts of T. F. Osborne (University of California, Irvine, CA) (11, 21). The plasmid pLXRE-Luc containing two LXR binding sites (between bp –249 and –149) in which the LXRE complex from SREBP-1c promoter was inserted into the pGL2 vector was a kind gift of H. Shimano (University of Tsukuba, Tsukuba, Japan) (44). The HCV NS5A coding sequence was generated by PCR amplification of HCV plasmid pCMV729-3010 (a gift of K. Shimotohno, Kyoto University, Kyoto, Japan). The plasmid pCMV729-3010 contains coding sequences of all of the HCV genotype 1b nonstructural proteins. The HCV genotype 1b NS4B expression plasmid under the transcriptional control of the human cytomegalovirus promoter was a kind gift of K. V. Konan (Stanford University, CA). The pFLAG-CMV-NS4B and pFLAG-CMV-core genes derived from genotype 3 were generated by amplification of the respective genes with the PCR primers containing HindIII and XbaI restriction sites, respectively. The PCR-generated fragments were cloned into the HindIII and XbaI sites of pFLAG-CMV-1 vector (Sigma) to produce pFLAG-CMV-NS4B and pFLAG-CMV-core, respectively. The mammalian expression vectors pcDNA3-Flag-SREBP-1 (amino acids 2 to 490) and pcDNA3-Flag-SREBP-2 (amino acids 2 to 485) were a gift of J. Ericsson (Ludwig Institute for Cancer Research, Uppsala, Sweden) (14).

Pyrrolidine dithiocarbamate (PDTC) and anti-FLAG monoclonal antibody were purchased from Sigma Chemical Co. Anti-SREBP-2 monoclonal (immunoglobulin G 1D2) and anti-SREBP-1 polyclonal antibodies were obtained from MBL, Japan, and Santa Cruz Biotechnology, CA. Antibodies to Akt, phospho-Akt-Ser473, PTEN (phosphatase and tensin homologue), and phospho-PTEN were obtained from Cell Signaling Technology. Anti-HCV core, anti-FAS, and antiphosphoserine monoclonal antibodies were purchased from Affinity BioReagent, CO; BD Transduction Labs, CA; and Alexis, CA, respectively. Anti-NS4B polyclonal antiserum was a kind gift of M. Kohara (Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan). LY294002, N-acetyl-Leu-Nle-CHO, and 1,2-bis(aminophenoxy)ethane-N,N,N',N'-tetraacetic acid-tetra(acetoxymethyl) ester (BAPTA-AM) were purchased from Calbiochem-Novabiochem Corp. (San Diego, CA).

HCV cell culture infection system. The JFH-1 genomic RNA (HCV genotype 2a) was transcribed and delivered into Huh-7 cells by electroporation or liposome-mediated transfection as described previously (44). For electroporation, cells were suspended in Cytomix buffer at 107 cells/ml. JFH-1 RNA (8 to 10 µg) was mixed with 0.2 ml of the cells in a 4-mm cuvette; a Bio-Rad Gene Pulser system was used to deliver a single pulse at 0.27 kV and 960 µF; and the cells were plated in 100-mm dishes. Liposome-mediated transfection was performed with Lipofectamine 2000 (Invitrogen) and 8 to 10 µg RNA (46). Cells were then plated in Dulbecco's modified Eagle's medium with 10% fetal bovine serum and passaged every 2 to 3 days; the presence of HCV RNA in the cells and corresponding cell culture supernatants was determined by quantitative reverse transcription PCR (RT-qPCR). The expression of HCV core or NS5A proteins was analyzed using Western blotting. The HCV cell culture supernatant was used to infect the naive Huh-7 cells at appropriate dilutions for 5 to 6 h of incubation at 37°C and 5% CO2 (39, 46). The level of HCV infection and the proteolytic processing of SREBPs were examined at days 2, 3, 5, and 7.

Immunoprecipitation and Western blot analysis. Exponentially growing Huh-7 cells alone and infected with HCV were transiently transfected with N-terminus FLAG-SREBP-1/2 expression vectors. At 36 h posttransfection cells were harvested and cell extracts were prepared by incubation in radioimmunoprecipitation assay buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate [SDS], 1 mM sodium orthovanadate, 1 mM sodium formate, 1 mM phenylmethylsulfonyl fluoride, 10 µg/ml aprotinin, 10 µg/ml leupeptin) for 30 min on ice. Immunoprecipitation (150 µg of total protein/5 µg antibody) was performed with anti-FLAG monoclonal antibody for 4 h. The immune complexes were incubated with protein A-Sepharose, washed three times with radioimmunoprecipitation assay buffer, and boiled for 5 min in SDS-polyacrylamide sample buffer. The samples were subjected to SDS-polyacrylamide gel electrophoresis (PAGE). Gels were electroblotted onto a nitrocellulose membrane (Amersham) in 25 mM Tris, 192 mM glycine, and 20% methanol by electrophoresis. Membranes were treated for 1 h in blocking buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.3% polyvinylpyrrolidone, 0.5% [wt/vol] Tween 20), probed with phosphoserine monoclonal antibody for 1 h, and washed twice for 10 min with blocking buffer followed by incubation with secondary antibody for 45 min. After an additional washing step with blocking buffer, immunoblots were visualized using the ECL detection system (Pierce).

For radiolabeling of proteins, cells were labeled for 4 h with 100 µCi of [32P]orthophosphate (Na2H32PO4) per ml (Perkin-Elmer, MA). Cells were washed several times with phosphate-buffered saline. SREBP-1 was immunoprecipitated using anti-SREBP-1 antiserum and subjected to SDS-PAGE and autoradiography.

Reprobing the immunoblots. The immunoblot membranes were submerged in stripping buffer (100 mM 2-mercaptoethanol, 2% SDS, 62.5 mM Tris-HCl, pH 6.7) and incubated at 50°C for 30 min with occasional shaking. The membranes were washed twice with blocking buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.3% polyvinylpyrrolidone, 0.5% [wt/vol] Tween 20), and immunodetection was performed with a different antibody as described above.

Luciferase assays. Huh-7 cells alone and infected with HCV were plated at a density of ~5 x 105 cells/60-mm dish and maintained in Dulbecco's modified Eagle's medium containing 10% fetal calf serum, penicillin (75 units/ml), and streptomycin (50 units/ml) at 37°C. Cells (~60% confluent) were transfected with 500 ng of luciferase reporter plasmid using Lipofectamine 2000 reagent (Life Technologies). Thirty hours posttransfection, cells were serum starved overnight followed by treatment with PDTC (100 µM) for 6 h, LY294002 (50 µM) for 12 h, and BAPTA-AM (50 µM) for 2 h. Cells were harvested, and cellular lysates were analyzed for luciferase expression using a luminometer (8). All transfections included Renilla expression vector to serve as an internal control.

Quantitative real-time RT-PCR. Lipogenic transcripts in Huh-7 and HCV-infected cells were quantified by real-time RT-PCR using an ABI PRISM 7000 Sequence Detector (Perkin-Elmer/Applied Biosystems). Total cellular RNAs were extracted using RNA STAT-60 (Tel-Test, Inc., Friendswood, TX), and the cDNA was reverse transcribed from 1 µg of total RNA using oligo(dT) primers. Quantitative RT-PCRs of lipogenic genes were carried out by using a SYBR green kit (QIAGEN, CA) and specific primer sets. The sequences for the primers and probes were designed using Primer Express software (Perkin-Elmer/Applied Biosystems). Amplification reactions were performed under the following conditions: 10 min at 95°C and then 40 cycles of 94°C for 15 s, 50°C for 30 s, and 72°C for 30 s followed by a dissociation protocol. Relative transcript levels were calculated using the {Delta}{Delta}CT method as specified by the manufacturer. The sequences of all the primers are shown in Table 1.


View this table:
[in this window]
[in a new window]

  		TABLE 1. Primers used in this study


arrow
RESULTS
 
In this study, we investigated the mechanism of activation of SREBPs, the master regulators of cholesterol/lipid metabolism in HCV-infected cells. To initiate this study, we incubated Huh-7 cells with HCV cell culture supernatant (HCV virions) derived from a recently described HCV genotype 2a infection system (27, 39, 46). Forty-eight hours postinfection, the levels of HCV infection were measured by analyzing HCV RNA levels in infected cells. An increased level of HCV RNA in cells infected with HCV was observed by quantitative RT-PCR (data not shown) that is consistent with previous studies (39, 46).

To examine whether HCV infection induces SREBP-1/2 proteolytic processing leading to the liberation of the N-terminal domain (68 kDa), cellular lysates from naive Huh-7 and HCV-infected cells were fractionated by SDS-PAGE and immunoblotted with anti-SREBP-1/2 antibodies. Western blot analysis of HCV-infected cellular lysates revealed an accumulation of mature forms of SREBP-1 (Fig. 1A, lane 2) compared to uninfected Huh-7 cells (Fig. 1A, lane 1). The expression of HCV core protein in HCV-infected cells represents the level of HCV infection (Fig. 1A, lane 2, bottom panel). Similarly, we observed the accumulation of the mature forms of SREBP-2 in HCV-infected cells (Fig. 1B, lane 2). Huh-7 cells incubated with delipidated medium for 24 h show a similar pattern of proteolytic cleavage (data not shown). To determine whether HCV infection also induces the transcriptional stimulation of SREBP-1c mRNA, total cellular RNA was extracted from Huh-7 and HCV-infected cells, and the level of SREBP-1c mRNA was quantified by real-time RT-PCR. The results showed increased SREBP-1c mRNA expression in HCV-infected cells (Fig. 1C, compare bar 1 with bar 2), indicating that HCV infection also regulates the biosynthesis of SREBP-1c mRNA. Similarly, the expression of SREBP-2 mRNA was also stimulated (data not shown). These results collectively suggest that HCV genotype 2a infection can induce both the transcriptional stimulation and the proteolytic processing of SREBPs. These activities lead to the production of mature forms of the proteins.


Figure 1
View larger version (24K):
[in this window]
[in a new window]

  		FIG. 1. HCV induces proteolytic processing of SREBP-1 and -2. (A and B) Uninfected and HCV-infected Huh-7 cells were harvested at 48 h. Whole-cell lysates from Huh-7 and HCV-infected cells were fractionated by SDS-PAGE and immunoblotted with anti-SREBP-1/2 monoclonal antibodies. Lanes 1, Huh-7 cell lysates; lanes 2, HCV-infected cell lysates. Bottom panels represent the expression of HCV core protein as a marker of HCV infection, and actin served as an internal protein loading control. (C) Transcriptional stimulation of SREBP-1 mRNA in HCV-infected cells. Total cellular mRNA was analyzed by using SREBP-1-specific primers. Bar 1, Huh-7 cells; bar 2, HCV-infected cells. The values represent the means and standard deviations of two independent experiments performed in duplicate. (D) HCV proteins induce proteolytic processing of mature SREBP-2. Whole-cell lysates from Huh-7 cells (lanes 1, 4, and 8 and unnumbered lane between lanes 2 and 3) and cells expressing HCV nonstructural proteins, pCMV729-3010 (lane 2), HCV NS4B (1b) (lane 3), NS4B (3a) (lane 5), NS5A (lane 6), HCV core (1b) (lane 7), and core (3a) (lane 9) were fractionated by SDS-PAGE and immunoblotted with anti-SREBP-2 monoclonal antibodies. The bottom panel represents the expression of individual HCV marker proteins.

Previously, the expression of HCV proteins (core and NS5A) derived from genotype 1b has been shown to regulate lipid metabolism (3, 35). To further demonstrate that the expression of HCV proteins from genotype 1b can induce the activation of SREBP-2, Huh-7 cells were transiently transfected with plasmid vectors expressing all the HCV nonstructural proteins (pCMV/729-3010), NS5A, and core proteins, all derived from genotype 1b. The results show that cells expressing all nonstructural proteins induce accumulation of SREBP-2 (Fig. 1D, lane 2), whereas HCV NS5A and core proteins fail to do so (Fig. 1D, lanes 6 and 7), suggesting that HCV nonstructural proteins other than NS5A might be involved in the activation of SREBP-2. To explore this possibility, we chose NS4B because the expression of NS4B has been previously shown to induce structural changes in the ER and induce ER stress (12, 45). ER stress has been demonstrated to trigger the proteolytic cleavage of precursor SREBPs into mature forms (16). Huh-7 cells were transiently transfected with vector expressing NS4B (genotype 1b). Western blot analysis of the cellular lysates shows the accumulation of mature SREBP-2 (Fig. 1D, lane 3). Since HCV genotype 3a is more commonly associated with steatosis (2), and since the HCV 3a core protein has been shown to be sufficient to induce triglyceride accumulation in vitro (1, 19), we decided to examine the effect of core and NS4B proteins derived from HCV genotype 3a on the maturation of SREBP-2. Huh-7 cells were transiently transfected with plasmid vectors expressing genotype 3a FLAG-HCV NS4B and core proteins. The results of this analysis show the accumulation of the mature form of SREBP-2 (Fig. 1D, lanes 5 and 9), suggesting that HCV genotype 3a core and NS4B proteins promote proteolytic processing of SREBP-2.

Phosphorylation of SREBPs via mitogen-activated protein (MAP) kinase and PI3-K-Akt has been shown to be necessary for transcriptional activation (24, 40). Our previous studies have shown that HCV-induced reactive oxygen synthase (ROS) and Ca2+ signaling activate cellular kinases (15, 41, 42). To demonstrate the role of HCV-induced activation of cellular kinases in inducing SREBP phosphorylation, HCV-infected cells were transiently transfected with the N-terminal domain of FLAG-tagged SREBP-1/2 and treated with antioxidant (PDTC), calcium chelator (BAPTA-AM), and PI3-K inhibitor (LY294002). Cellular lysates were immunoprecipitated with anti-FLAG monoclonal antibody and subjected to Western blot analysis using antiphosphoserine monoclonal antibody. Increased phosphorylation of SREBP-1/2 was observed in HCV-infected cells (Fig. 2A and B, lanes 2), but in the presence of antioxidant, calcium chelator, and PI3-K inhibitor, these proteins were not phosphorylated (Fig. 2A and B, lanes 3 to 5). To further confirm the role of HCV infection in inducing the phosphorylation of SREBPs, Huh-7 and HCV-infected Huh-7 cells were radiolabeled with phosphorus-32 (Na2H32PO4) and cellular lysates were immunoprecipitated with anti-SREBP-1 antibody followed by SDS-PAGE and autoradiography. The SREBP-1 was 32P labeled in vivo in HCV-infected cells (Fig. 2C, lane 2). These results together demonstrate that HCV stimulates the phosphorylation of SREBPs via oxidative stress and calcium signaling.


Figure 2
View larger version (14K):
[in this window]
[in a new window]

  		FIG. 2. HCV induces phosphorylation of SREBP-1/2. (A and B) Huh-7 cells and HCV-infected cells were transiently transfected with N-terminus FLAG-tagged SREBP-1/2. Whole-cell lysates were immunoprecipitated with anti-FLAG monoclonal antibody, fractionated by SDS-PAGE, and immunoblotted with antiphosphoserine monoclonal antibody. Lanes 1 and 2, lysates from Huh-7 and HCV-infected cells expressing FLAG-SREBP-1 (A) and FLAG-SREBP-2 (B). Lanes 3, 4, and 5, HCV-infected cells were treated with an antioxidant, PDTC (100 µM for 6 h); a calcium chelator, BAPTA-AM (50 µM for 2 h); and a PI3-K inhibitor, LY294002 (50 µM for 12 h), respectively. The bottom panels represent the expression of N-terminus FLAG-tagged SREBP-1/2 and HCV core protein during Western blot analysis. (C) In vivo phosphorylation of SREBP-1 in HCV-infected cells. HCV-infected cells were metabolically labeled with [32P]orthophosphate (100 µCi) for 4 h. Cellular lysates were immunoprecipitated with anti-SREBP-1 antibody and subjected to SDS-PAGE followed by autoradiography. Lane 1, Huh-7 cell lysate; lane 2, HCV-infected cell lysate.

To provide biological evidence for SREBP-2 activation, cell-based luciferase reporter assays were performed. The luciferase reporter gene (pSynSRE-Luc) under the control of the SRE derived from the HMG-CoA synthase gene and a mutant plasmid, pJS-15, that contains point mutations in the SREs, were used (11). These reporter plasmids were transfected into HCV-infected cells as well as cotransfected with the plasmid vectors encoding individual HCV proteins (NS4B, NS5A, and core). Thirty-six hours posttransfection cellular lysates were assayed for luciferase activity. The results displayed increased activity of pSynSRE-Luc promoter reporter in the presence of all the nonstructural proteins (Fig. 3A, bar 4), NS4B (1b) (bar 2), NS4B (3a) (bar 5), and core (3a) (bar 6). The expression of NS5A and core derived from genotype 1b did not stimulate the luciferase activity (Fig. 3A, bars 3 and 7). Similar induction of luciferase activity was observed in HCV-infected cells (Fig. 3B, black bar). Next, HCV-infected cells (Fig. 3B, black bar) and cells transiently transfected with HCV proteins (pCMV/729-3010 and NS4B) (Fig. 3B, white bar and gray bar) were incubated with antioxidant (PDTC), calcium chelator (BAPTA-AM), and PI3-K inhibitor (LY294002). The luciferase activity of pSynSRE-Luc was reduced in the presence of antioxidant, Ca2+ chelator, and PI3-K inhibitor (Fig. 3B), suggesting that SREBP-2 transactivation is mediated via Ca2+ signaling and oxidative stress. These results further indicate a functional role of PI3-K in HCV-mediated activation of SREBPs, most likely via direct phosphorylation. The pJS-15 reporter plasmid harboring mutated SREBP-2 binding sites did not show stimulation of luciferase activity (Fig. 3A, bar 8).


Figure 3
View larger version (12K):
[in this window]
[in a new window]

  		FIG. 3. HCV proteins transactivate SREBP-2. (A) Luciferase reporter gene assays. Huh-7 cells were transfected with 500 ng of SRE-responsive SynSRE-Luc (wild type) (bar 1) and JS-15 (containing mutated SRE binding sites) luciferase plasmids along with plasmids expressing HCV proteins NS4B (1b) (bar 2), NS4B (3a) (bar 5), NS5A (bar 3), all nonstructural proteins (pCMV/729-3010) (bars 4 and 5), core (1b) (bar 7), and core (3a) (bar 6). Thirty-six hours posttransfection cellular lysates were assayed for luciferase activity. The data represent means ± standard deviations of three independent experiments performed in duplicate; the lowest level of significance was P < 0.01. The bottom panel represents the immunoblot showing the expression of individual HCV proteins as indicated by the individual expression vector used in transient transfections. 729-3010 is an expression vector that encodes all NS proteins (NS2 to NS4b) (15). NS5a expression is shown below as a representative nonstructural protein. (B) SynSRE-Luc (wild type) reporter plasmid was transfected in HCV-infected cells (black bars) as well as cotransfected with pCMV/729-3010 (white bars) and pCMV-NS4B (gray bars). Thirty-six hours posttransfection cells were treated with antioxidant (100 µM PDTC for 4 h), calcium chelator (50 µM BAPTA-AM for 2 h), and PI3-K inhibitor (50 µM LY294002 for 12 h), and cellular lysates were assayed for luciferase activity. The data represent means ± standard deviations of three independent experiments performed in duplicate; the lowest level of significance was P < 0.01.

Similarly, to assess the transactivity of SREBP-1 in HCV-infected cells, the luciferase reporter gene under the control of SREBP-1 derived from the FAS gene (FAS-700-Luc) and a plasmid (FAS-mut-Luc) that contains mutated SREBP-1 binding sites were used (21). Huh-7 and HCV-infected cells were transiently transfected with these luciferase reporter plasmids and treated with antioxidant (PDTC), Ca2+ chelator (BAPTA-AM), and PI3-K inhibitor (LY294002). Thirty-six hours posttransfection cellular lysates were assayed for luciferase activity. The results displayed increased activity of FAS-700-Luc promoter reporter in HCV-infected cells (Fig. 4A, bar 2) and were dramatically reduced in the presence of antioxidant (PDTC), Ca2+ chelator (BAPTA-AM), and PI3-K inhibitor (LY294002) (Fig. 4A, bars 3 to 5), suggesting that SREBP-1-mediated FAS-Luc activity was mediated via Ca2+ signaling, ROS, and PI3-K-Akt pathway activity. The expression of FAS-mut-Luc did not show stimulation of luciferase activity (Fig. 4A, bar 6). These results unambiguously establish that HCV induces activation of SREBP-1 and -2, via phosphorylation leading to stimulation of SREBP target genes.


Figure 4
View larger version (33K):
[in this window]
[in a new window]

  		FIG. 4. HCV transactivates SREBP-1. (A) Luciferase reporter gene assay. Huh-7 and HCV-infected cells were transfected with 500 ng of FAS-700-Luc (wt) and FAS-mut-Luc reporter plasmids as described for Fig. 3. Results are shown as means (± standard deviations) of two independent experiments, each performed in duplicate. (B) Western blot assays. Cellular lysates from Huh-7 and HCV-infected cells were subjected to Western blot analysis using respective antibodies as indicated. Lanes 1, Huh-7 cell lysates; lanes 2, HCV-infected cell lysates. (C) Quantitative real-time PCR analysis. Total cellular mRNA was extracted, and cDNAs were prepared from Huh-7 (lane 1) and HCV-infected (lane 2) cells. Equal amounts of cDNAs were subjected to quantitative RT-PCR using LXR-specific primers. Hypoxanthine phosphoribosyltransferase (HPRT) mRNA was used as an internal control. The results represent means ± standard deviations of two independent experiments performed in triplicate. (D) Huh-7 cells and HCV-infected cells were transfected with LXR-responsive pLXRE-Luc luciferase plasmid derived from the SREBP-1c gene. Thirty-six hours posttransfection cellular lysates were prepared and assayed for luciferase activity. The data represent means ± standard deviations of three independent experiments performed in duplicate.

It is known that Akt can increase the expression of the SREBP-1 gene (30). Previously, we have shown that HCV activates the PI3-K-Akt pathway (15). To demonstrate if HCV-induced Akt activation (via phosphorylation) can stimulate the expression of FAS protein in HCV-infected cells, cellular lysates from cells infected with HCV were subjected to SDS-PAGE followed by Western blot analysis. The results show enhanced expression of FAS in HCV-infected cells (Fig. 4B, lane 2). An activated form of Akt (serine phosphorylated) is also produced in HCV-infected cellular lysates (Fig. 4B, lane 2). Since the tumor suppressor protein PTEN regulates the activity of PI3-K-Akt, we examined the status of PTEN in HCV-infected cells. The Western blot analysis of HCV-infected Huh-7 cells revealed the presence of a phosphorylated form of PTEN (Fig. 4B, lane 2), suggesting that phospho-PTEN (inactive PTEN) might favor the activity of PI3-K-Akt in HCV-infected cells (13). PTEN was not phosphorylated in uninfected Huh-7 cells.

Recently, LXR has been shown to induce SREBP-1c at the transcriptional level (17). To demonstrate if the activation of SREBP-1c in HCV-infected cells was upregulated through LXR activation, we first examined the mRNA levels of LXR in HCV-infected cells. The quantitative real-time PCR results demonstrate transcriptional stimulation of LXR mRNA in HCV-infected cells (Fig. 4C, lane 2). To examine if induced LXR in HCV-infected cells can stimulate SREBP-1c, a luciferase reporter gene derived from SREBP-1c promoter/enhancer, which contains the binding site for LXR (pLXRE-Luc), was transfected into Huh-7 and HCV-infected cells. Luciferase activity was assayed at 36 h posttransfection. LXRE-Luc activity was stimulated in HCV-infected cells (Fig. 4D, bar 2). These results suggest that HCV gene expression stimulates the activation of SREBP-1c at the transcriptional level through LXR receptor.

To determine if HCV-infected cells can induce lipogenic target genes and cholesterol/lipid biosynthetic pathways, we analyzed the transcripts of lipogenic genes by quantitative RT-PCR analysis. The mRNAs analyzed include HMG-CoA reductase, squalene synthase, ATP citrate lyase, acetyl-CoA carboxylase, FAS, and stearoyl-CoA desaturase. HCV infection generally enhanced levels of these lipogenic transcripts (Fig. 5). These data collectively indicate that HCV infection transcriptionally stimulates hepatic lipid biosynthesis.


Figure 5
View larger version (33K):
[in this window]
[in a new window]

  		FIG. 5. HCV infection induces the expression of lipogenic transcripts. Total cellular mRNA was extracted, and cDNAs were prepared from Huh-7 and HCV-infected cells. Equal amounts of cDNAs were subjected to quantitative RT-PCR using SYBR green probe. This experiment was performed in duplicates. Hypoxanthine phosphoribosyltransferase mRNA was used as a standard internal control. HMGCR, HMG-CoA reductase; Sq Synth, squalene synthase; ACL, ATP citrate lyase; SCD, stearoyl-CoA desaturase; ACC1, acetyl-CoA carboxylase.


arrow
DISCUSSION
 
Several studies have suggested that HCV alters the expression of genes associated with lipid metabolism (6, 26, 37). Microarray analysis of liver biopsy samples from HCV-infected chimpanzees provided the evidence for the induction of genes involved in lipid metabolism and cholesterol/fatty acid biosynthesis (6, 37). HCV induces the formation of cytosolic lipid droplets onto which HCV structural and nonstructural proteins have been shown to colocalize (35). In chronic hepatitis C, genotype 3a is more commonly associated with steatosis than other genotypes (2), suggesting the presence of steatogenic sequences in the viral genome. The transgenic mice expressing whole HCV genome or core gene derived from genotype 1 developed steatosis (26, 29). HCV genotype 3-infected patients who respond to antiviral therapy reverse steatosis, suggesting a direct causal relationship between HCV infection and hepatic accumulation of lipid (31, 33).

We previously reported that HCV subgenomic replicon (genotype 1b) affects apolipoprotein B-100 secretion and MTP activity (10). In support of this observation, MTP gene expression and enzymatic activity in liver biopsy specimens from patients with chronic hepatitis C were inversely correlated with the histological grade of steatosis (28). The molecular mechanism(s) underlying the altered cholesterol/lipid homeostasis in response to HCV gene expression has not been characterized.

In the present study, we investigated the mechanism of activation of SREBPs in the course of HCV infection in the cell culture system. The results described here show that the expression of HCV proteins derived from genotype 1b can induce proteolytic processing of SREBP-2 (Fig. 1D). Here, we show that NS4B derived either from genotype 1 or from genotype 3 is capable of proteolytic cleavage of SREBP-2, probably through ER stress and structural changes that are known to be caused in the ER membrane by this protein. ER stress triggers the proteolytic cleavage of precursor SREBPs into mature forms (16, 23). We have previously described the ability of the HCV nonstructural proteins to induce ER stress (38). NS4B is an integral membrane protein that has been shown to induce the formation of an ER-derived membranous web-like structure and induce ER stress (12, 45). It is also possible that the induction of the membranous web as a novel platform for HCV replication activities demands higher levels of cholesterol. Stimulation of transcriptionally active SREBPs meets that challenge. We observed that HCV core and NS4B proteins derived from genotype 3a were more efficient in the proteolytic processing of SREBP-2 (Fig. 1D). This is consistent with the previous studies in which HCV core protein derived from genotype 3a was shown to induce significant accumulation of triglycerides (1, 20). The molecular mechanisms underlying the significant involvement of HCV genotype 3 compared to other genotypes in steatosis remain to be characterized. The severity of steatosis in patients with genotype 3 has been shown to correlate with higher viral load (33).

Recently, evidence has been accumulating that SREBPs are not only involved in cholesterol-regulated events but are also regulatory targets of MAP kinase and the PI3-K-Akt pathway. We have previously shown that HCV gene expression induces activation of cellular kinases such as JAK, Src, MAP kinase, and PI3-K-Akt via oxidative stress and calcium signaling (41, 42). In this study, we observed an increase in serine phosphorylation of SREBPs in HCV-infected cells (Fig. 2), which is mediated by HCV-induced calcium signaling, subsequent elevation of ROS levels, and activation of PI3 kinase. Phosphorylation of SREBPs may aid in the generation of homo- and heterodimers, which in turn influence the transactivation potential of SREBPs (24, 30). Previously, MAP kinase and PI3-K-Akt cascades have been shown to be necessary for transcriptional activation of SREBPs (24, 30, 40). Recently, the activity of mature SREBP-1 was shown to be regulated by hyperphosphorylation during the cell cycle, suggesting that SREBP-1 may provide a link between lipid synthesis, proliferation, and cell growth (5).

The biological activity of SREBP-2 was demonstrated by using cell-based luciferase reporter assays. We observed an increased activity of SRE-controlled luciferase activity in the presence of the HCV proteins NS4B (genotypes 1b and 3a) and core (genotype 3a), suggesting that individual HCV proteins, regardless of HCV genotype, are able to induce the transactivation activities of SREBPs.

In the present study, we set out to investigate the possible mechanism by which SREBPs trans-activate gene expression in the nucleus. Our results demonstrate that pSynSRE-Luc activities were reduced in the presence of antioxidants and Ca2+ chelator, suggesting that SREBP transactivation is mediated via Ca2+ signaling and oxidative stress induced by HCV. It has been postulated that constitutive activation of the PI3-K-Akt pathway may be involved in fatty acid and cholesterol accumulation in several pathologies and cancers (30). It is known that the PI3-K-Akt kinases increase the expression of the SREBP-1 gene (30). Previously, we have shown that HCV activates the PI3-K-Akt pathway (41). In this study, we observed that pSynSRE-Luc activity was reduced in the presence of PI3-K inhibitor, suggesting that the PI3-K-Akt pathway stimulates the phosphorylation of SREBPs. Previously, the role of PI3-K-Akt in SREBP-1-mediated FAS promoter activity has been demonstrated (20, 30). Furthermore, our results revealed the presence of phosphorylated PTEN during the course of HCV infection. Phospho-PTEN is an inactive form of PTEN phosphatase, which favors the activation of PI3-K-Akt in HCV-infected cells (13).

The regulation of SREBP-1a and SREBP-2 proteolytic cleavage by cellular sterol content is well defined, but less is known about the regulation of SREBP-1c, the predominant isoform in the liver (36). Recently, LXR has been shown to induce SREBP-1c at the transcriptional level (17). In this analysis, we observed transcriptional stimulation of LXR mRNA as well as increased pLXRE-Luc activity in HCV-infected cells. These results suggest that HCV gene expression stimulates the activation of SREBP-1c at the transcriptional level at least in part through LXR transcriptional activation. How HCV induces LXR activation and subsequently SREBP-1c is not clearly understood.

It is known that HCV is dependent on the cholesterol/fatty acid synthetic pathway for efficient RNA replication (37). Genome-wide transcriptional analyses of HCV infection suggest that a high-level of HCV replication is associated with the modulation of genes involved in lipid biosynthesis (37). In this study, HCV infection generally enhanced the levels of lipogenic transcripts (Fig. 5). These results are consistent with the previous studies conducted with chimpanzees, transgenic mice, and Huh-7 cells expressing the genotype 1b HCV replicons (6, 22, 26). These results are also consistent with the previous studies in which Huh-7 cells expressing the genotype 1b HCV replicon induced lipogenic genes (22). These data collectively indicate that HCV infection transcriptionally stimulates hepatic lipid biosynthesis. Increased cholesterol and fatty acid synthesis may play a key role(s) in efficient HCV replication.

This study demonstrates that HCV infection based on genotype 2a leads to stimulation of lipogenic genes through activation of all three isoforms of SREBPs. Our results demonstrate that mature forms of SREBP-1 and -2 are further activated via oxidative stress induced by HCV. This stimulation occurs by the action of activated PI3-K. Moreover, NS4B and core proteins derived from genotype 3a also contribute to the activation of SREBPs through proteolytic cleavage. The transcriptional stimulation of FAS and SREBP-1c suggests a possible model of HCV-mediated lipogenesis through LXR activation. Activated SREBPs may represent a new potential therapeutic target in the pathogenesis of HCV infection associated with steatosis.


arrow
ACKNOWLEDGMENTS
 
This work is supported by a grant from NIH to A.S. (U19 A1066313 and DK61566) and grants from the Swiss National Science Foundation (3200-63549.00 and 3200B0-103727) to F.N.

We thank T. Wakita for the generous gift of HCV genotype 2a (JFH-1) infectious cDNA.


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: Department of Medicine, Division of Infectious Diseases, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093. Phone: (858) 822-1750. Fax: (858) 822-1749. E-mail: asiddiqui{at}ucsd.edu Back

{triangledown} Published ahead of print on 16 May 2007. Back

{dagger} Present address:. Department of Microbiology and Immunology, The Chicago Medical School, RFUMS, North Chicago, IL 60064. Back


arrow
REFERENCES
 
    1
  1. Abid, K., V. Pazienza, A. de Gottardi, L. Rubbia-Brandt, B. Conne, P. Pugnale, C. Rossi, A. Mangia, and F. Negro. 2005. An in vitro model of hepatitis C virus genotype 3a-associated triglycerides accumulation. J. Hepatol. 42:744-751.[CrossRef][Medline]
    2. 2
  2. Asselah, T., L. Rubbia-Brandt, P. Marcellin, and F. Negro. 2006. Steatosis in chronic hepatitis C: why does it really matter? Gut 55:123-130.[Free Full Text]
    3. 3
  3. Barba, G., F. Harper, T. Harada, M. Kohara, S. Goulinet, Y. Matsuura, G. Eder, Z. Schaff, M. J. Chapman, T. Miyamura, and C. Brechot. 1997. Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. Proc. Natl. Acad. Sci. USA 94:1200-1205.[Abstract/Free Full Text]
    4. 4
  4. Bartenschlager, R., and V. Lohmann. 2000. Replication of hepatitis C virus. J. Gen. Virol. 81:1631-1648.[Free Full Text]
    5. 5
  5. Bengoechea-Alonso, M. T., T. Punga, and J. Ericsson. 2005. Hyperphosphorylation regulates the activity of SREBP1 during mitosis. Proc. Natl. Acad. Sci. USA 102:11681-11686.[Abstract/Free Full Text]
    6. 6
  6. Bigger, C. B., B. Guerra, K. M. Brasky, G. Hubbard, M. R. Beard, B. A. Luxon, S. M. Lemon, and R. E. Lanford. 2004. Intrahepatic gene expression during chronic hepatitis C virus infection in chimpanzees. J. Virol. 78:13779-13792.[Abstract/Free Full Text]
    7. 7
  7. Brown, M. S., and J. L. Goldstein. 1999. A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. Proc. Natl. Acad. Sci. USA 96:11041-11048.[Abstract/Free Full Text]
    8. 8
  8. de Wet, J. R., K. V. Wood, M. Deluka, D. R. Helinski, and S. Subramani. 1987. Firefly luciferase gene: structure and expression in mammalian cells. Mol. Cell. Biol. 7:723-737.
    9. 9
  9. Di Bisceglie, A. M. 1997. Hepatitis C and hepatocellular carcinoma. Hepatology 26:34S-38S.[CrossRef][Medline]
    10. 10
  10. Domitrovich, A. M., D. J. Felmlee, and A. Siddiqui. 2005. Hepatitis C virus nonstructural proteins inhibit apolipoprotein B100 secretion. J. Biol. Chem. 280:39802-39808.[Abstract/Free Full Text]
    11. 11
  11. Dooley, K. A., S. Millinder, and T. F. Osborne. 1998. Sterol regulation of 3-hydroxy-3-methylglutaryl-coenzyme A synthase gene through a direct interaction between sterol regulatory element binding protein and the trimeric CCAAT-binding factor/nuclear factor Y. J. Biol. Chem. 273:1349-1356.[Abstract/Free Full Text]
    12. 12
  12. Egger, D., B. Wolk, R. Gosert, L. Bianchi, H. E. Blum, D. Moradpour, and K. Bienz. 2002. Expression of hepatitis C virus proteins induces distinct membrane alteration including a candidate viral replication complex. J. Virol. 76:5974-5984.[Abstract/Free Full Text]
    13. 13
  13. Gericke, A., M. Munson, and A. H. Ross. 2006. Regulation of the PTEN phosphatases. Gene 374:1-9.[CrossRef][Medline]
    14. 14
  14. Giandomenico, V., S. Maria, G. Eva, and J. Ericsson. 2003. Coactivator-dependent acetylation stabilizes members of the SREBP family of transcription factors. Mol. Cell. Biol. 23:2587-2599.[Abstract/Free Full Text]
    15. 15
  15. Gong, G., G. Waris, R. Tanveer, and A. Siddiqui. 2001. Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kB. Proc. Natl. Acad. Sci. USA 98:9599-9604.[Abstract/Free Full Text]
    16. 16
  16. Harding, H. P., Y. Zhang, S. Khersonsky, S. Marciniak, D. Scheuner, R. J. Kaufman, N. Javitt, Y. T. Chang, and D. Ron. 2005. Bioactive small molecules reveal antagonism between the integrated stress response and sterol-regulated gene expression. Cell Metab. 2:361-371.[CrossRef][Medline]
    17. 17
  17. Hegarty, B. D., A. Bobard, I. Hainault, P. Ferre, P. Bossard, and F. Foufelle. 2005. Distinct roles of insulin and liver X receptor in the induction and cleavage of sterol regulatory element binding protein-1c. Proc. Natl. Acad. Sci. USA 102:791-796.[Abstract/Free Full Text]
    18. 18
  18. Horton, J. D., J. L. Goldstein, and M. S. Brown. 2002. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Investig. 109:1125-1131.[CrossRef][Medline]
    19. 19
  19. Hui, J. M., J. Kench, G. C. Farrell, R. Lin, D. Samarasinghe, C. Liddle, K. Byth, and J. George. 2002. Genotype-specific mechanism for hepatic steatosis in chronic hepatitis C infection. J. Gastroenterol. Hepatol. 17:873-881.[CrossRef][Medline]
    20. 20
  20. Jackel-Cram, C., A. L. Babiuk, and L. Qiang. 2007. Up-regulation of fatty acid synthase promoter by hepatitis C virus core protein: genotype-3a core has a stronger effect than genotype-1b core. J. Hepatol. 46:999-1008.[CrossRef][Medline]
    21. 21
  21. Joseph, S. B., B. A. Laffitte, P. H. Patel, L. A. Watson, K. E. Matsukuma, R. Walczak, J. L. Collins, T. F. Osborne, and P. Tontonoz. 2002. Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by liver X receptors. J. Biol. Chem. 277:11019-11025.[Abstract/Free Full Text]
    22. 22
  22. Kapadia, S. B., and F. V. Chisari. 2005. Hepatitis C virus replication is regulated by host geranylgeranylation and fatty acids. Proc. Natl. Acad. Sci. USA 102:2561-2566.[Abstract/Free Full Text]
    23. 23
  23. Kaplowitz, N., and C. Ji. 2006. Unfolding new mechanism of alcoholic liver disease in the endoplasmic reticulum. J. Gastroenterol. Hepatol. 21:S7-S9.[CrossRef][Medline]
    24. 24
  24. Kotzka, J., D. Muller-Wieland, G. Roth, L. Kremer, M. Munck, S. Schurmann, B. Knebel, and W. Krone. 2000. Sterol regulatory element binding proteins (SREBP)-1a and SREBP-2 are linked to the MAP-kinase cascade. J. Lipid Res. 41:99-108.[Abstract/Free Full Text]
    25. 25
  25. Lee, J. N., and J. Ye. 2004. Proteolytic activation of sterol regulatory element-binding protein induced by cellular stress through depletion of Insig-1. J. Biol. Chem. 279:45257-45265.[Abstract/Free Full Text]
    26. 26
  26. Lerat, H., M. Honda, M. R. Beard, K. Loesch, J. Sun, Y. Yang, M. Okuda, R. Gosert, S. Y. Xiao, S. A. Weinman, and S. M. Lemon. 2002. Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. Gastroenterology 122:352-365.[CrossRef][Medline]
    27. 27
  27. Lindenbach, B. D., M. J. Evans, A. J. Syder, B. Wolk, T. L. Tellinghuisen, C. C. Liu, T. Maruyama, R. O. Hynes, D. R. Burton, J. A. McKeating, and C. M. Rice. 2005. Complete replication of hepatitis C virus in cell culture. Science 309:623-626.[Abstract/Free Full Text]
    28. 28
  28. Mirandola, S., S. Realdon, J. Iqbal, M. Gerotto, F. D. Pero, G. Bortoletto, M. Marcolongo, A. Vario, C. Datz, M. Mahmood, and A. Alberti. 2006. Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis. Gastroenterology 130:1661-1669.[CrossRef][Medline]
    29. 29
  29. Moriya, K., H. Yotsuyanagi, Y. Shintani, H. Fujie, K. Ishibashi, Y. Matsuura, T. Miyamura, and K. Koike. 1997. Hepatitis C virus core protein induces steatosis in transgenic mice. J. Gen. Virol. 78:1527-1531.[Abstract]
    30. 30
  30. Porstmann, T., B. Griffiths, Y. L. Chung, O. Delpuech, J. R. Griffiths, J. Downward, and A. Schulze. 2005. PKB/Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP. Oncogene 24:6465-6481.[Medline]
    31. 31
  31. Poynard, T., V. Ratziu, J. McHutchison, M. Manns, Z. Goodman, S. Zeuzem, Z. Younossi, and J. Albrecht. 2003. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 38:75-85.[CrossRef]
    32. 32
  32. Reed, K. E., and C. M. Rice. 2000. Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties. Curr. Top. Microbiol. Immunol. 242:55-84.[Medline]
    33. 33
  33. Rubbia-Brandt, L., R. Quadri, K. Abid, E. Giostra, P. J. Male, G. Mentha, L. Spahr, J. P. Zarski, B. Borisch, A. Hadengue, and F. Negro. 2000. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J. Hepatol. 33:106-115.[CrossRef][Medline]
    34. 34
  34. Scheuer, P. J., P. Ashrafzaden, S. Sherlock, D. Brown, and G. M. Dusheiko. 1992. The pathology of chronic hepatitis C. Hepatology 15:567-571.[Medline]
    35. 35
  35. Shi, S. T., S. J. Polyak, H. Tu, D. R. Taylor, D. R. Gretch, and M. M. Lai. 2002. Hepatitis C virus NS5A colocalizes with the core protein on lipid droplets and interacts with apolipoprotein. Virology 292:198-210.[CrossRef][Medline]
    36. 36
  36. Shimomura, I., H. Shimano, J. D. Horton, J. L. Goldstein, and M. S. Brown. 1997. Differential expression of exon 1a and 1c in mRNAs for sterol regulatory element binding protein-1 in human and mouse organs and cultured cells. J. Clin. Investig. 99:838-845.[Medline]
    37. 37
  37. Su, A. I., J. P. Pezacki, L. Wodiccka, A. D. Brideau, L. Supekova, R. Thimme, S. Wieland, J. Bukh, R. H. Purcell, P. G. Schultz, and F. V. Chisari. 2002. Genomic analysis of the host response to hepatitis C virus infection. Proc. Natl. Acad. Sci. USA 99:15669-15674.[Abstract/Free Full Text]
    38. 38
  38. Tardif, K. D., K. Mori, and A. Siddiqui. 2002. Hepatitis C virus subgenomic replicons induce endoplasmic reticulum stress activating an intracellular signaling pathway. J. Virol. 76:7453-7459.[Abstract/Free Full Text]
    39. 39
  39. Wakita, T., T. Pietschmann, T. Kato, T. Date, M. Miyamoto, Z. Zhao, K. Murthy, A. Habermann, H. G. Krausslich, M. Mizokami, R. Bartenschlager, and T. J. Liang. 2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11:791-796.[CrossRef][Medline]
    40. 40
  40. Wang, D., and H. S. Sul. 1998. Insulin stimulation of the fatty acid synthase promoter is mediated by the phosphatidylinositol 3-kinase pathway: Involvement of protein kinase B/Akt. J. Biol. Chem. 273:25420-25426.[Abstract/Free Full Text]
    41. 41
  41. Waris, G., and A. Siddiqui. 2005. Hepatitis C virus stimulates the expression of cyclooxygenase-2 via oxidative stress: role of prostaglandin E2 in RNA replication. J. Virol. 79:9725-9734.[Abstract/Free Full Text]
    42. 42
  42. Waris, G., J. Turkson, T. Hassanein, and A. Siddiqui. 2005. Hepatitis C virus constitutively activates STAT-3 via oxidative stress: role of STAT-3 in HCV replication. J. Virol. 79:1569-1580.[Abstract/Free Full Text]
    43. 43
  43. Xu, Z., J. T. Choi, T. S. Yen, W. Lu, A. Strohecker, S. Govindrajan, D. Chien, M. Silby, and J. Ou. 2001. Synthesis of a novel hepatitis C virus protein by ribosomal frameshift. EMBO J. 20:3840-3848.[CrossRef][Medline]
    44. 44
  44. Yoshikawa, T., H. Shimano, M. A. Kudo, N. Yahagi, A. H. Hasty, T. Matsuzaka, S. Okazaki, Y. Tamura, Y. Iizuka, K. Ohashi, J. I. Osuga, K. Harada, T. Gotoda, S. Kimura, S. Ishibashi, and N. Yamada. 2001. Identification of liver X receptor-retinoid X receptor as an activator of the sterol regulatory element-binding protein 1c gene promoter. Mol. Cell. Biol. 21:2991-3000.[Abstract/Free Full Text]
    45. 45
  45. Zheng, Y., B. Gao, L. Ye, L. Kong, W. Jing, X. Yang, Z. Wu, and L. Ye. 2005. Hepatitis C virus non-structural protein NS4B can modulate an unfolded protein response. J. Microbiol. 43:529-536.[Medline]
    46. 46
  46. Zhong, J., P. Gastaminza, G. Cheng, S. Kapadia, T. Kato, D. R. Burton, S. F. Wieland, S. L. Uprichard, T. Wakita, and F. V. Chisari. 2005. Robust hepatitis C virus infection in vitro. Proc. Natl. Acad. Sci. USA 102:9294-9299.[Abstract/Free Full Text]

Journal of Virology, August 2007, p. 8122-8130, Vol. 81, No. 15
0022-538X/07/$08.00+0     doi:10.1128/JVI.00125-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Lavie, L., Lavie, P. (2009). Molecular mechanisms of cardiovascular disease in OSAHS: the oxidative stress link. Eur Respir J 33: 1467-1484 [Abstract] [Full Text]  
  • Park, C.-Y., Jun, H.-J., Wakita, T., Cheong, J. H., Hwang, S. B. (2009). Hepatitis C Virus Nonstructural 4B Protein Modulates Sterol Regulatory Element-binding Protein Signaling via the AKT Pathway. J. Biol. Chem. 284: 9237-9246 [Abstract] [Full Text]  
  • Kanda, T., Steele, R., Ray, R., Ray, R. B. (2008). Hepatitis C Virus Core Protein Augments Androgen Receptor-Mediated Signaling. J. Virol. 82: 11066-11072 [Abstract] [Full Text]  
  • Oem, J.-K., Jackel-Cram, C., Li, Y.-P., Zhou, Y., Zhong, J., Shimano, H., Babiuk, L. A., Liu, Q. (2008). Activation of sterol regulatory element-binding protein 1c and fatty acid synthase transcription by hepatitis C virus non-structural protein 2. J. Gen. Virol. 89: 1225-1230 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Waris, G.
Right arrow Articles by Siddiqui, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Waris, G.
Right arrow Articles by Siddiqui, A.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»